Oncology research is advancing faster than ever.
As ASCO approaches, the industry is preparing to showcase breakthroughs in precision medicine, biomarker-driven therapies, and novel cancer treatments that are transforming outcomes for patients worldwide.
But while science has evolved rapidly, many of the operational technology and enablement supporting oncology clinical trials have not.
Increasing clinical trial complexity, fragmented oversight, and delayed operational visibility are making it harder for studies to stay on track — even as the urgency to bring therapies to patients grows.
For patients living with advanced or rare cancers, operational delays in clinical trials are not just business problems. They can directly affect how quickly patients gain access to potentially life-saving therapies.
Oncology Trials Are More Complex to Execute Than Ever
Modern oncology trials are becoming operationally more demanding:
- More specific inclusion and exclusion criteria
- Biomarker-specificity
- Multi-site global trial execution
- Increasing protocol complexity
- Larger volumes of operational and clinical data
- Increasing competition with other trials
One oncology study may generate hundreds of operational signals across hundreds of sites every single day. The challenge is no longer simply collecting data, but proactively anticipating operational risk and coordinating action before issues escalate.
Yet many trial teams still rely on fragmented systems, manual oversight, and periodic review processes designed for a much simpler clinical trial environment.
The Role of AI in Oncology Operational Intelligence
AI and connected operational intelligence have the potential to fundamentally reshape how oncology trials are monitored and managed.
AI in clinical trials can’t replace clinical expertise but it can empower teams and help prevent execution failures:
- Continuously monitor trial activity instead of relying on periodic review
- Connect protocol requirements with live operational data
- Detect emerging risks earlier
- Surface site-level patterns across fragmented systems
- Measure effectiveness across sponsors, CROs, CRAs, and study teams in real time
The future of oncology trial execution will depend on moving from passive oversight to active monitoring, coordinated action, and earlier risk mitigation. The faster teams can identify and resolve operational risk, the greater the likelihood that studies remain on track, stay inspection-ready, and ultimately bring new therapies to patients faster.
Final Thoughts
Innovation Depends on Execution
Research continues to transform what is scientifically possible for patients with cancer.
Now the industry faces a different challenge: ensuring clinical trial operations can keep pace with the speed and complexity of innovation itself.
As the oncology community gathers at ASCO to showcase the future of cancer care, it is worth recognizing that breakthrough therapies depend not only on scientific discovery — but also on the operational systems and execution required to bring those therapies to patients.
At Espresso, we believe the future of clinical trials will require continuous operational intelligence. We’re working with pharmaceutical companies and research organizations to improve operational visibility across clinical trials so teams can anticipate risk earlier, coordinate action faster, and keep studies on track from protocol to approval.
